Biological Effects of Short-Term or Prolonged Administration of 9-[2-(Phosphonomethoxy)Propyl]Adenine (Tenofovir) to Newborn and Infant Rhesus Macaques

Antimicrobial Agents and Chemotherapy

Volumn 48, Issue 5, 2004, Pages 1469-1487

  Van Rompay, Koen K A ^a   Brignolo, Laurie L ^a   Meyer, Dennis J ^c,f   Jerome, Christopher ^d   Tarara, Ross ^a   Spinner, Abigail ^a   Hamilton, Marta ^c,g   Hirst, Linda L ^a   Bennett, David R ^a   Canfield, Don R ^a   Dearman, Trish G ^a   Von Morgenland, Wilhelm ^a   Allen, Phil C ^a   Valverde, Celia ^a   Castillo, Alesha B ^b   Martin, R Bruce ^b   Samii, Valerie F ^e   Bendele, Ray ^c,g   Desjardins, John ^c,g   Marthas, Marta L ^a   Pedersen, Niels C ^b   Bischofberger, Norbert ^c   more..

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c GILEAD SCIENCES   (United States)

^d SkeleTech Inc   (United States)

^e OHIO STATE UNIVERSITY   (United States)

^f CHARLES RIVER LABORATORIES   (United States)

^g OSI PHARMACEUTICALS INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

TENOFOVIR;

AMINOACIDURIA; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BONE DISEASE; CONTROLLED STUDY; DOSE RESPONSE; DRUG CLEARANCE; DRUG SAFETY; FANCONI RENOTUBULAR SYNDROME; FEMALE; GLUCOSURIA; GROWTH RETARDATION; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HYPOPHOSPHATEMIA; MACACA; MALE; NONHUMAN; OSTEOMALACIA; PRIORITY JOURNAL;

ADENINE; ANIMALS; ANIMALS, NEWBORN; ANTI-HIV AGENTS; AREA UNDER CURVE; BLOOD CHEMICAL ANALYSIS; BONE AND BONES; BONE DENSITY; DENSITOMETRY, X-RAY; DOSE-RESPONSE RELATIONSHIP, DRUG; FANCONI SYNDROME; FEMALE; GLYCOSURIA; HALF-LIFE; MACACA MULATTA; MALE; ORGANOPHOSPHORUS COMPOUNDS; PHOSPHONIC ACIDS; PHOSPHORUS; TIME FACTORS; WEIGHT GAIN;

EID: 11144358258     PISSN: 00664804     EISSN: None     Source Type: Journal    
DOI: 10.1128/AAC.48.5.1469-1487.2004     Document Type: Article

References (65)

1. Alpers, C. E., C. C. Tsai, K. L. Hudkins, Y. Cui, L. Kuller, R. E. Benveniste, J. M. Ward, and W. R. Morton. 1997. Focal segmental glomerulosclerosis in primates infected with a simian immunodeficiency virus. AIDS Res. Hum. Retrovir. 13:413-424.
2. Barditch-Crovo, P., S. G. Deeks, A. Collier, S. Safrin, D. F. Coakley, M. Miller, B. P. Kearney, R. L. Coleman, P. D. Lamy, J. O. Kahn, I. McGowan, and P. S. Lietman. 2001. Phase I/II trial of the pharmacokinetics, safety, and antiretroviral activity of tenofovir disoproxil fumarate in human immunodeficiency virus type 1-infected adults. Antimicrob. Agents Chemother. 45: 2733-2739.
3. Biesecker, G., S. Karimi, J. Desjardins, D. Meyer, B. Abbott, R. Bendele, and F. Richardson. 2003. Evaluation of mitochondrial DNA content and enzyme levels in tenofovir DF-treatment rats, rhesus monkeys and woodchucks. Antivir. Res. 58:217-225.
4. Birkus, G., M. J. M. Hitchcock, and T. Cihlar. 2002. Assessment of mitochondrial toxicity in human cells treated with tenofovir: comparison with other nucleoside reverse transcriptase inhibitors. Antimicrob. Agents Chemother. 46:716-723.
5. Bourne, G. H. 1975. Nutrition of the rhesus monkey, p. 97-116. In G. H. Bourne (ed.), The rhesus monkey, vol. II. Management, reproduction, and pathology. Academic Press, Inc., New York, N.Y.
6. Calcagno, P. L., and M. I. Rubin. 1963. Renal extraction of para-aminohippurate in infants and children. J. Clin. Investig. 42:1632-1639.
7. Carr, A., J. Miller, J. A. Eisman, and D. A. Cooper. 2001. Osteopenia in HIV-infected men: association with asymptomatic lactic acidemia and lower weight pre-antiretroviral therapy. AIDS 15:703-709.
8. Carr, A., K. Samaras, S. Burton, M. Law, J. Freund, D. J. Chisholm, and D. A. Cooper. 1998. A syndrome of peripheral lipodystrophy, hyperlipidemia and insulin resistance in patients receiving HIV protease inhibitors. AIDS 12:F51-F58.
9. Centers for Disease Control and Prevention. 1997. Update: trends in AIDS incidence-United States, 1996. Morbid. Mortal. Wkly. Rep. 46:862-867.
10. Cihlar, T., E. S. Ho, D. C. Lin, and A. S. Mulato. 2001. Human renal organic anion transporter 1 (hOAT1) and its role in the nephrotoxicity of antiviral nucleotide analogs. Nucleosides Nucleotides Nucleic Acids 20:641-648.
11. Clarke, B. L., A. G. Wynne, D. M. Wilson, and L. A. Fitzpatrick. 1995, Osteomalacia associated with adult Fanconi's syndrome: clinical and diagnostic features. Clin. Endocrinol. 43:479-490.
12. Coca, S., and M. A. Perazella. 2002. Rapid communication: acute renal failure associated with tenofovir: evidence of drug-induced nephrotoxicity. Am. J. Med. Sci. 324:342-344.
13. Créput, C., G. Gonzalez-Canali, G. Hill, C. Piketty, M. Kazatchkine, and D. Nochy. 2003. Renal lesions in HIV-1 positive patient treated with tenofovir. AIDS 17:935-937.
14. Cundy, K. C., P. Barditch-Crovo, R. E. Walker, A. C. Collier, D. Ebeling, J. Toole, and H. S. Jaffe. 1995. Clinical pharmacokinetics of adefovir in human immunodeficiency virus type 1-infected patients. Antimicrob. Agents Chemother. 39:2401-2405.
15. Cundy, K. C., C. Sueoka, G. R. Lynch, L. Griffin, W. A. Lee, and J.-P. Shaw. 1998. Pharmacokinetics and bioavailability of the anti-human immunodeficiency virus nucleotide analog 9-[(R)-2-(phosphonomethoxy)propyl]adenine (PMPA) in dogs. Antimicrob. Agents Chemother. 42:687-690.
16. Deeks, S. G., P. Barditch-Crovo, P. S. Lietman, F. Hwang, K. C. Cundy, J. F. Rooney, N. S. Hellmann, S. Safrin, and J. Kahn. 1998. Safety, pharmacokinetics, and antiretroviral activity of intravenous 9-[2-(R)-(phosphonomethoxy)propyl]adenine, a novel anti-human immunodeficiency virus (HIV) therapy, in HIV-infected adults. Antimicrob. Agents Chemother. 42:2380-2384.
17. Eshleman, S. H., M. Mracna, L. A. Guay, M. Deseyve, S. Cunningham, M. Mirochnick, P. Musoke, T. Fleming, M. G. Fowler, L. M. Mofenson, F. Mmiro, and J. B. Jackson. 2001. Selection and fading of resistance mutations in women and infants receiving nevirapine to prevent HIV-1 vertical transmission (HIVNET012). AIDS 15:1951-1957.
18. Fisher, E. J., K. Chaloner, D. L. Cohn, L. Bjorling Grant, B. Alston, C. L. Brosgart, B. Schmetter, W. El-Sadr, and J. Sampson for the Terry Beirn Community Programs for Clinical Research on AIDS. 2001. The safety and efficacy of adefovir dipivoxil in patients with advanced HIV disease: a randomized, placebo-controlled trial. AIDS 15:1695-1700.
19. Gallant, J., and S. Deresinski. 2003. Tenofovir disoproxil fumarate. Clin. Infect. Dis. 37:944-950.
20. Goodwin, B. T., and C. P. Jerome. 1987. Iliac biopsy for histomorphometric analysis of trabecular bone in cynomolgus monkeys and baboons. Lab. Anim. Sci. 37:213-216.
21. Grihnau, A. A. M., and L. G. M. Geijsberts. 1981. Developmental stages in the rhesus monkey (Macaca mulatta). Springer-Verlag, Berlin, Germany.
22. Harrigan, P. R., M. D. Miller, P. McKenna, Z. L. Brumme, and B. Larder. 2002. Phenotypic susceptibilities to tenofovir in a large panel of clinically derived human immunodeficiency virus type 1 isolates. Antimicrob. Agents Chemother. 46:1067-1072.
23. Hill, L. R., K. R. Hess, L. C. Stephens, R. E. Price, and K. N. Gray. 2001. Correlation of kidney weight and volume and selected skeletal parameters to sex in the adult rhesus monkey (Macaca mulatta). J. Med. Primatol. 30:56-60.
24. Jerome, C. P., and P. E. Peterson. 2001. Nonhuman primate models in skeletal research. Bone 29:1-6.
25. Kahn, J., S. Lagakos, M. Wulfsohn, D. Cherng, M. Miller, J. Cherrington, D. Hardy, G. Beall, R. Cooper, R. Murphy, N. Basgoz, E. Ng, S. Deeks, D. Winslow, J. J. Toole, and D. Coakley for the GS-408 Study Team. 1999. Efficacy and safety of adefovir dipivoxil with antiretroviral therapy. A randomized controlled trial. JAMA 282:2305-2312.
26. Karras, A., M. Lafaurie, A. Furco, A. Bourgarit, D. Droz, D. Sereni, C. Legendre, F. Martinez, and J.-M. Molina. 2003. Tenofovir-related nephrotoxicity in human immunodeficiency virus-infected patients: three cases of renal failure, Fanconi syndrome, and nephrogenic diabetes insipidus. Clin. Infect. Dis. 36:1070-1073.
27. Lawal, A., E. S. Engelson, J. Wang, S. B. Heymsfield, and D. P. Kotler. 2001. Equivalent osteopenia in HIV-infected individuals studied before and during the era of highly active antiretroviral therapy. AIDS 15:278-280.
28. Lian, L.-M., Y.-C. Chang, C.-C. Yang, J.-C. Yang, K.-P. Kao, and M.-Y. Chung. 1994. Adult Fanconi syndrome with proximal muscle weakness and hypophosphatemic osteomalacia: report of a case. J. Formos. Med. Assoc. 93:709-714.
29. Lopez-Anaya, A., J. D. Unadkat, L. A. Schumann, and A. L. Smith. 1990. Pharmacokinetics of zidovudine (azidothymidine). II. Development of metabolic and renal clearance pathways in the neonate. J. Acquir. Immune Defic. Syndr. 3:1052-1058.
30. Madge, S., S. Kinloch-de-Loes, D. Mercey, M. A. Johnson, and I. V. D. Weller. 1999. Lipodystrophy in patients naive to HIV protease inhibitors. AIDS 13:735-737.
31. Meyer, D. J., and J. W. Harvey. 1998. Veterinary laboratory medicine. Interpretation and diagnosis, p. 157-186. The W. B. Saunders Co., Philadelphia, Pa.
32. Mondy, K., K. Yarasheski, W. G. Powderly, M. Whyte, S. Claxton, D. DeMarco, M. Hofffmann, and P. Tebas. 2003. Longitudinal evolution of bone mineral density and bone markers in human immunodeficiency virus-infected individuals. Clin. Infect. Dis. 36:482-490.
33. Moore, A., A. Vashisht, C. A. Sabin, A. Mocroft, S. Madge, A. N. Phillips, J. W. W. Studd, and M. A. Johnson. 2001. Reduced bone mineral density in HIV-positive individuals. AIDS 15:1731-1733.
34. Mora, S., N. Sala, D. Bricalli, G. Zuin, G. Chiumello, and A. Vigano. 2001. Bone mineral loss through increased bone turnover in HIV-infected children treated with highly active antiretroviral therapy. AIDS 15:1823-1829.
35. National Research Council. 1978. Nutrient requirements of nonhuman primates. National Academy of Sciences, Washington, D.C.
36. National Research Council. 1996. Guide for the care and use of laboratory animals. Committee on Care and Use of Laboratory Animals, Institute of Laboratory Animal Resources. National Academy Press, Washington, D.C.
37. Parfitt, A. M., M. K. Drezner, F. H. Glorieux, J. A. Kanis, H. Malluche, P. J. Meunier, S. M. Ott, and R. R. Recker. 1987. Bone histomorphometry: standardization of nomenclature, symbols, and units. Report of the ASBMR Histomorphometry Nomenclature Committee. J. Bone Miner. Res. 2:595-610.
38. a. Peyrière, H., J. Reynes, I. Rouanet, N. Daniel, C. Merle de Boever, J.-M. Mauboussin, H. Leray, L. Moachon, D. Vincent, and D. Salmon-Céron. 2004. Renal tubular dysfunction associated with tenofovir therapy. Report of 7 cases. J. Acquir. Immune Defic. Syndr. 35:269-273.
39. Pope, N. S., K. G. Gould, D. C. Anderson, and D. R. Mann. 1989. Effects of age and sex on bone density in the rhesus monkey. Bone 10:109-112.
40. Roberts, J., E. W. Ford, and J. L. Southers. 1998. Part A. Urinary system, p. 312-323. In B. T. Bennett, C. R. Abee, and R. Henrickson (ed.), Nonhuman primates in biomedical research diseases. Academic Press, Inc., San Diego, Calif.
41. Saint-Marc, T., M. Partisani, I. Poizot-Martin, F. Bruno, O. Rouviere, J.-M. Lang, J.-A. Gastaut, and J.-L. Touraine. 1999. A syndrome of peripheral fat wasting (lipodystrophy) in patients receiving long-term nucleoside analogue therapy. AIDS 13:1659-1667.
42. Segal, L. S., R. C. Palumbo, and W. W. Robertson. 1995. The development of rickets as a complication of chemotherapy for the treatment of Wilm's tumor. Orthopedics 18:261-264.
43. Sharer, J. E., L. A. Shipley, M. R. Vandenbranden, S. N. Binkley, and S. A. Wrighton. 1995. Comparisons of phase I and phase II in vitro hepatic enzyme activities of human, dog, rhesus monkey, and cynomolgus monkey. Drug Metab. Dispos. 23:1231-1241.
44. Shaw, J. P., C. M. Sueoka, R. Oliyai, W. A. Lee, M. N. Arimilli, C. Kim, and K. C. Cundy. 1997. Metabolism and pharmacokinetics of a novel oral prodrug of 9-[(R)-2-(phosphonomethoxy)propyl]adenine (PMPA) in dogs. Pharm. Res. 14:1824-1829.
45. Squires, K., A. Pozniak, G. Pierone, C. R. Steinhart, D. Berger, N. C. Bellos, S. L. Becker, M. Wulfsohn, M. D. Miller, J. J. Toole, D. F. Coakley, and A. Cheng for the Study 907 Team. 2003. Tenofovir disoproxil fumarate in nucleoside-resistant HIV-1 infection. A randomized trial. Ann. Intern. Med. 139:313-320.
46. Tarantal, A. F., A. Castillo, J. E. Ekert, N. Bischofberger, and R. B. Martin. 2002. Fetal and maternal outcome after administration of tenofovir to gravid rhesus monkeys (Macaca mulatta). J. Acquir. Immune Defic. Syndr. 29:207-220.
47. Tarantal, A. F., M. L. Marthas, J.-P. Shaw, K. Cundy, and N. Bischofberger. 1999. Administration of 9-[2-(R)-(phosphonomethoxy)propyl] adenine (PMPA) to gravid and infant rhesus macaques (Macaca mulatta): safety and efficacy studies. J. Acquir. Immune Defic. Syndr. Hum. Retrovirol. 20:323-333.
48. Tebas, P., W. G. Powderly, S. Claxton, D. Marin, S. Tantisiriwat, L. Teitelbaum, and K. E. Yarasheski. 2000. Accelerated bone mineral loss in HIV-infected patients receiving potent antiretroviral therapy. AIDS 14:F63-F67.
49. Tsai, C.-C., K. E. Follis, T. W. Beck, A. Sabo, N. Bischofberger, and P. J. Dailey. 1997. Effects of (R)-9-(2-phosphonylmethoxypropyl)adenine monotherapy on chronic SIV infection. AIDS Res. Hum. Retrovir. 13:707-712.
50. Van Rompay, K. K. A., C. J. Berardi, N. L. Aguirre, N. Bischofberger, P. S. Lietman, N. C. Pedersen, and M. L. Marthas. 1998. Two doses of PMPA protect newborn macaques against oral simian immunodeficiency virus infection. AIDS 12:F79-F83.
51. Van Rompay, K. K. A., J. M. Cherrington, M. L. Marthas, C. J. Berardi, A. S. Mulato, A. Spinner, R. P. Tarara, D. R. Canfield, S. Telm, N. Bischofberger, and N. C. Pedersen. 1996. 9-[2-(Phosphonomethoxy)propyl]adenine therapy of established simian immunodeficiency virus infection in infant rhesus macaques. Antimicrob. Agents Chemother. 40:2586-2591.
52. Van Rompay, K. K. A., J. M. Cherrington, M. L. Marthas, P. D. Lamy, P. J. Dailey, D. R. Canfield, R. P. Tarara, N. Bischofberger, and N. C. Pedersen. 1999. 9-[2-(Phosphonomethoxy)propyl]adenine (PMPA) therapy prolongs survival of infant macaques inoculated with simian immunodeficiency virus with reduced susceptibility to PMPA. Antimicrob. Agents Chemother. 43: 802-812.
53. Van Rompay, K. K. A., P. J. Dailey, R. P. Tarara, D. R. Canfield, N. L. Aguirre, J. M. Cherrington, P. D. Lamy, N. Bischofberger, N. C. Pedersen, and M. L. Marthas. 1999. Early short-term 9-[2-(phosphonomethoxy) propyl]adenine treatment favorably alters subsequent disease course in simian immunodeficiency virus-infected newborn rhesus macaques. J. Virol. 73:2947-2955.
54. Van Rompay, K. K. A., M. L. Marthas, J. D. Lifson, C. J. Berardi, G. M. Vasquez, E. Agatep, Z. A. Dehqanzada, K. C. Cundy, N. Bischofberger, and N. C. Pedersen. 1998. Administration of 9-[2-(phosphonomethoxy)propyl] adenine (PMPA) for prevention of perinatal simian immunodeficiency virus infection in rhesus macaques. AIDS Res. Hum. Retrovir. 14:761-773.
55. Van Rompay, K. K. A., M. L. Marthas, R. A. Ramos, C. P. Mandell, E. K. McGowan, S. M. Joye, and N. C. Pedersen. 1992. Simian immunodeficiency virus (SIV) infection of infant rhesus macaques as a model to test antiretroviral drug prophylaxis and therapy: oral 3′-azido-3′-deoxythymidine prevents SIV infection. Antimicrob. Agents Chemother. 36:2381-2386.
56. Van Rompay, K. K. A., M. B. McChesney, N. L. Aguirre, K. A. Schmidt, N. Bischofberger, and M. L. Marthas. 2001. Two low doses of tenofovir protect newborn macaques against oral simian immunodeficiency virus infection. J. Infect. Dis. 184:429-438.
57. Van Rompay, K. K. A., M. D. Miller, M. L. Marthas, N. A. Margot, P. J. Dailey, R. P. Tarara, D. R. Canfield, J. M. Cherrington, N. L. Aguirre, N. Bischofberger, and N. C. Pedersen. 2000. Prophylactic and therapeutic benefits of short-term 9-[2-(phosphonomethoxy)propyl]adenine (PMPA) administration to newborn macaques following oral inoculation with simian immunodeficiency virus with reduced susceptibility to PMPA. J. Virol. 74: 1767-1774.
58. Van Rompay, K. K. A., M. G. Otsyula, M. L. Marthas, C. J. Miller, M. B. McChesney, and N. C. Pedersen. 1995. Immediate zidovudine treatment protects simian immunodeficiency virus-infected newborn macaques against rapid onset of AIDS. Antimicrob. Agents Chemother. 39:125-131.
59. a. Van Rompay, K. K. A., R. Singh, L. Brignolo, J. R. Lawson, K. A. Schmidt, B. Pahar, D. R. Canfield, R. P. Tarara, N. Bischofberger, and M. Marthas. The clinical benefits of tenofovir for simian immunodeficiency virus-infected macaques are larger than predicted by its effects on standard viral and immunological parameters. J. Acquir. Immune Defic. Syndr., in press.
60. +-cell-mediated suppression of virulent simian immunodeficiency virus during tenofovir treatment. J. Virol., in press.
61. Verhelst, D., M. Monge, J.-L. Meynard, B. Fouqueray, B. Mougenot, P.-M. Girard, P. Ronco, and J. Rossert. 2002. Fanconi syndrome and renal failure induced by tenofovir: a first case report. Am. J. Kidney Dis. 40:1331-1333.
62. Wainberg, M. A., M. D. Miller, Y. Quan, H. Salomon, A. S. Mulato, P. D. Lamy, N. A. Margot, K. E. Anton, and J. M. Cherrington. 1999. In vitro selection and characterization of HIV-1 with reduced susceptibility to PMPA. Antivir. Ther. 4:87-94.
63. Watson, D. C., and J. J. Farley. 1999. Efficacy of and adherence to highly active antiretroviral therapy in children infected with human immunodeficiency virus type 1. Pediatr. Infect. Dis. J. 18:682-689.
64. West, J. R., H. W. Smith, and H. Chasis. 1948. Glomerular filtration rate, effective renal blood flow, and maximal tubular excretory capacity in infancy. J. Pediatr. 32:10-18.
65. Zoetis, T., and M. Hurtt. 2003. Species comparison of anatomical and functional renal development. Birth Defects Res. Part B Dev. Reprod. Toxicol. 68:111-120.